Intellia Therapeutics, Inc. (NTLA)
NTLA Stock Price Chart
Explore Intellia Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze NTLA price movements and trends.
NTLA Company Profile
Discover essential business fundamentals and corporate details for Intellia Therapeutics, Inc. (NTLA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 May 2016
Employees
403.00
Website
https://www.intelliatx.comCEO
John Leonard
Description
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
NTLA Financial Timeline
Browse a chronological timeline of Intellia Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.80, while revenue estimate is $12.98m.
Earnings released on 11 May 2026
EPS came in at -$0.81 surpassing the estimated -$0.92 by +11.96%, while revenue for the quarter reached $15.05m , beating expectations by +8.99%.
Earnings released on 26 Feb 2026
EPS came in at -$0.83 surpassing the estimated -$0.99 by +16.16%, while revenue for the quarter reached $23.02m , beating expectations by +92.10%.
Earnings released on 6 Nov 2025
EPS came in at -$0.92 surpassing the estimated -$1.02 by +9.80%, while revenue for the quarter reached $13.78m , beating expectations by +13.22%.
Earnings released on 7 Aug 2025
EPS came in at -$0.99 surpassing the estimated -$1.03 by +3.88%, while revenue for the quarter reached $14.25m , beating expectations by +1.29%.
Earnings released on 8 May 2025
EPS came in at -$1.10 surpassing the estimated -$1.26 by +12.70%, while revenue for the quarter reached $16.63m , beating expectations by +39.34%.
Earnings released on 27 Feb 2025
EPS came in at -$1.24 surpassing the estimated -$1.32 by +6.06%, while revenue for the quarter reached $12.87m , beating expectations by +18.54%.
Earnings released on 7 Nov 2024
EPS came in at -$1.34 surpassing the estimated -$1.37 by +2.19%, while revenue for the quarter reached $9.11m , beating expectations by +2.32%.
Earnings released on 8 Aug 2024
EPS came in at -$1.31 falling short of the estimated -$1.21 by -8.26%, while revenue for the quarter reached $6.96m , missing expectations by -63.69%.
Earnings released on 9 May 2024
EPS came in at -$1.06 surpassing the estimated -$1.35 by +21.48%, while revenue for the quarter reached $28.94m , beating expectations by +151.61%.
Earnings released on 22 Feb 2024
EPS came in at -$1.46 surpassing the estimated -$1.47 by +0.68%, while revenue for the quarter reached $1.92m , missing expectations by -85.06%.
Earnings released on 9 Nov 2023
EPS came in at -$1.38 surpassing the estimated -$1.52 by +9.21%, while revenue for the quarter reached $11.99m , missing expectations by -3.68%.
Earnings released on 3 Aug 2023
EPS came in at -$1.40 falling short of the estimated -$1.32 by -6.06%, while revenue for the quarter reached $13.59m , beating expectations by +12.53%.
Earnings released on 4 May 2023
EPS came in at -$1.17 surpassing the estimated -$1.41 by +17.02%, while revenue for the quarter reached $12.61m , beating expectations by +6.56%.
Earnings released on 23 Feb 2023
EPS came in at -$1.40 matching the estimated -$1.40, while revenue for the quarter reached $13.57m , beating expectations by +19.76%.
Earnings released on 3 Nov 2022
EPS came in at -$1.49 falling short of the estimated -$1.31 by -13.74%, while revenue for the quarter reached $13.27m , beating expectations by +11.61%.
Earnings released on 4 Aug 2022
EPS came in at -$1.33 falling short of the estimated -$1.31 by -1.53%, while revenue for the quarter reached $14.03m , beating expectations by +49.00%.
Earnings released on 5 May 2022
EPS came in at -$1.96 falling short of the estimated -$1.11 by -76.58%, while revenue for the quarter reached $11.25m , beating expectations by +31.75%.
Earnings released on 24 Feb 2022
EPS came in at -$1.09 falling short of the estimated -$0.91 by -19.78%, while revenue for the quarter reached $12.85m , beating expectations by +55.57%.
Earnings released on 4 Nov 2021
EPS came in at -$0.97 falling short of the estimated -$0.85 by -14.12%, while revenue for the quarter reached $7.20m , missing expectations by -24.09%.
Earnings released on 5 Aug 2021
EPS came in at -$1.01 falling short of the estimated -$0.61 by -65.57%, while revenue for the quarter reached $6.55m , beating expectations by +17.36%.
NTLA Stock Performance
Access detailed NTLA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
